FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289731636> ?p ?o ?g. }

• W4289731636 endingPage "908" @default.
• W4289731636 startingPage "902" @default.
• W4289731636 abstract "Medication samples of anti-VEGF agents can represent a good option for retina specialists to provide timely treatment for newly converted neovascular age-related macular degeneration (nvAMD) while prior-authorizations (PA) are pending. Our study examines the effect of medication sample use (ranibizumab or aflibercept) on future anti-vascular endothelial growth factor (VEGF) agent selection in nvAMD.Retrospective cohort study.nvAMD patients who underwent an initial anti-VEGF injection with a sample medication were compared to nvAMD control patients who never received a medication sample.Charts from 2017 through 2020 were reviewed for data regarding demographics, anti-VEGF agent selection, and visual acuity outcomes for both groups. The utilization of different anti-VEGF agents in each group was compared at various time points using chi-square tests for independence of proportions.Anti-VEGF agent selection for the first four injections and at one year were examined.Adherence to the initial agent was high between first and subsequent injections (2nd, 3rd, 4th injection, and 1 year) in sample (96.2%, 95.9%, 91.9%, 93.4%, respectively), and control groups (98.1%, 94.2%, 94.9%, 87.8%, respectively). Bevacizumab usage was significantly lower among eyes receiving samples relative to controls at the second (1.9% vs. 38.7%, p < .001), third (3.1% vs. 41.3%, p < .001), fourth injections (4.7% vs. 40.4%, p < .001), and at 1 year (0% vs. 33.8%, p < .001). Aflibercept usage was significantly higher in sample eyes relative to controls at the second (78.3% vs. 43.4%, p < .001), third (76.3% vs. 41.5%, p < .001), and fourth injections (76.7% vs. 43.4%, p < .001), and at 1 year (77.0% vs. 52.7%, p < .001).Sample medications in nvAMD may be initiated for many reasons, including awaiting PA approval. Our study found that eyes receiving a sample anti-VEGF agent (ranibizumab or aflibercept) for their initial injection were less likely to receive bevacizumab at future visits relative to eyes that did not receive an anti-VEGF sample, even after one year of treatment. Given the persistent use of more expensive medications at subsequent injections for patients who were initiated on samples, insurance payors may consider waiving PA requirements for bevacizumab to avoid a paradoxical increase in health-care costs." @default.
• W4289731636 created "2022-08-04" @default.
• W4289731636 creator A5003464199 @default.
• W4289731636 creator A5006337681 @default.
• W4289731636 creator A5011881123 @default.
• W4289731636 creator A5017569999 @default.
• W4289731636 creator A5035711783 @default.
• W4289731636 creator A5038698286 @default.
• W4289731636 creator A5042804572 @default.
• W4289731636 creator A5047246417 @default.
• W4289731636 creator A5050919831 @default.
• W4289731636 creator A5050971382 @default.
• W4289731636 creator A5051486317 @default.
• W4289731636 creator A5058727483 @default.
• W4289731636 creator A5060404172 @default.
• W4289731636 creator A5061294501 @default.
• W4289731636 creator A5066039903 @default.
• W4289731636 creator A5069204345 @default.
• W4289731636 creator A5069517897 @default.
• W4289731636 creator A5076751606 @default.
• W4289731636 creator A5085111515 @default.
• W4289731636 creator A5090613199 @default.
• W4289731636 date "2022-08-03" @default.
• W4289731636 modified "2023-10-18" @default.
• W4289731636 title "The Effect of Sample Medication Use on Subsequent Anti-VEGF Agent Selection for Neovascular Age-Related Macular Degeneration" @default.
• W4289731636 cites W1960776002 @default.
• W4289731636 cites W1975926216 @default.
• W4289731636 cites W1987748266 @default.
• W4289731636 cites W2002892655 @default.
• W4289731636 cites W2044637793 @default.
• W4289731636 cites W2052198397 @default.
• W4289731636 cites W2059038525 @default.
• W4289731636 cites W2082732485 @default.
• W4289731636 cites W2555189142 @default.
• W4289731636 cites W2956957447 @default.
• W4289731636 cites W3035509592 @default.
• W4289731636 cites W3135287449 @default.
• W4289731636 doi "https://doi.org/10.1080/08820538.2022.2107398" @default.
• W4289731636 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35923110" @default.
• W4289731636 hasPublicationYear "2022" @default.
• W4289731636 type Work @default.
• W4289731636 citedByCount "0" @default.
• W4289731636 crossrefType "journal-article" @default.
• W4289731636 hasAuthorship W4289731636A5003464199 @default.
• W4289731636 hasAuthorship W4289731636A5006337681 @default.
• W4289731636 hasAuthorship W4289731636A5011881123 @default.
• W4289731636 hasAuthorship W4289731636A5017569999 @default.
• W4289731636 hasAuthorship W4289731636A5035711783 @default.
• W4289731636 hasAuthorship W4289731636A5038698286 @default.
• W4289731636 hasAuthorship W4289731636A5042804572 @default.
• W4289731636 hasAuthorship W4289731636A5047246417 @default.
• W4289731636 hasAuthorship W4289731636A5050919831 @default.
• W4289731636 hasAuthorship W4289731636A5050971382 @default.
• W4289731636 hasAuthorship W4289731636A5051486317 @default.
• W4289731636 hasAuthorship W4289731636A5058727483 @default.
• W4289731636 hasAuthorship W4289731636A5060404172 @default.
• W4289731636 hasAuthorship W4289731636A5061294501 @default.
• W4289731636 hasAuthorship W4289731636A5066039903 @default.
• W4289731636 hasAuthorship W4289731636A5069204345 @default.
• W4289731636 hasAuthorship W4289731636A5069517897 @default.
• W4289731636 hasAuthorship W4289731636A5076751606 @default.
• W4289731636 hasAuthorship W4289731636A5085111515 @default.
• W4289731636 hasAuthorship W4289731636A5090613199 @default.
• W4289731636 hasBestOaLocation W42897316362 @default.
• W4289731636 hasConcept C118487528 @default.
• W4289731636 hasConcept C126322002 @default.
• W4289731636 hasConcept C141071460 @default.
• W4289731636 hasConcept C167135981 @default.
• W4289731636 hasConcept C2776403814 @default.
• W4289731636 hasConcept C2776694085 @default.
• W4289731636 hasConcept C2777802072 @default.
• W4289731636 hasConcept C2778257484 @default.
• W4289731636 hasConcept C2778749236 @default.
• W4289731636 hasConcept C2781100027 @default.
• W4289731636 hasConcept C71924100 @default.
• W4289731636 hasConcept C72563966 @default.
• W4289731636 hasConceptScore W4289731636C118487528 @default.
• W4289731636 hasConceptScore W4289731636C126322002 @default.
• W4289731636 hasConceptScore W4289731636C141071460 @default.
• W4289731636 hasConceptScore W4289731636C167135981 @default.
• W4289731636 hasConceptScore W4289731636C2776403814 @default.
• W4289731636 hasConceptScore W4289731636C2776694085 @default.
• W4289731636 hasConceptScore W4289731636C2777802072 @default.
• W4289731636 hasConceptScore W4289731636C2778257484 @default.
• W4289731636 hasConceptScore W4289731636C2778749236 @default.
• W4289731636 hasConceptScore W4289731636C2781100027 @default.
• W4289731636 hasConceptScore W4289731636C71924100 @default.
• W4289731636 hasConceptScore W4289731636C72563966 @default.
• W4289731636 hasIssue "7-8" @default.
• W4289731636 hasLocation W42897316361 @default.
• W4289731636 hasLocation W42897316362 @default.
• W4289731636 hasLocation W42897316363 @default.
• W4289731636 hasOpenAccess W4289731636 @default.
• W4289731636 hasPrimaryLocation W42897316361 @default.
• W4289731636 hasRelatedWork W1994426946 @default.
• W4289731636 hasRelatedWork W2084462826 @default.
• W4289731636 hasRelatedWork W2331198753 @default.
• W4289731636 hasRelatedWork W2332982868 @default.

• next